A proof-of-concept randomized trial testing a single intravenous infusion of tocilizumab versus placebo in 30 participants with depression and elevated CRP ≥3 mg l−1 (ref. 66) found improvements in quality of life, fatigue and cognitive outcomes, but not in the severity of depressive symptoms67. This evidence concerns the gene CRP and depressive disorder.